Menu
Search
|

Menu

Close
X

OptiNose Inc OPTN.OQ (NASDAQ Stock Exchange Global Select Market)

24.47 USD
-- (--)
As of Jun 19
chart
Previous Close 24.47
Open --
Volume --
3m Avg Volume 41,928
Today’s High --
Today’s Low --
52 Week High 25.74
52 Week Low 15.01
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.75 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
1
FY17
0
FY16
48
EPS (USD)
FY18
-0.808
FY17
-1.684
FY16
-2.227
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.75
Price to Sales (TTM)
vs sector
--
5.71
Price to Book (MRQ)
vs sector
--
5.37
Price to Cash Flow (TTM)
vs sector
--
23.33
Total Debt to Equity (MRQ)
vs sector
--
16.44
LT Debt to Equity (MRQ)
vs sector
--
12.17
Return on Investment (TTM)
vs sector
--
14.38
Return on Equity (TTM)
vs sector
--
16.07

EXECUTIVE LEADERSHIP

Joseph Scodari
Independent Chairman of the Board, Since 2017
Salary: kr19,726.00
Bonus: --
Ramy Mahmoud
President, Chief Operating Officer, Since 2010
Salary: $437,750.00
Bonus: $328,313.00
Peter Miller
Chief Executive Officer, Director, Since 2010
Salary: $535,600.00
Bonus: $482,040.00
Larry Pickering
Independent Vice Chairman of the Board, Since 2017
Salary: --
Bonus: --
Keith Goldan
Chief Financial Officer, Since 2017
Salary: $329,340.00
Bonus: $222,010.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1020 Stony Hill Rd Ste 300
YARDLEY   PA   19067-5539

Phone: +1267.3643500

OptiNose, Inc. is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other. The Company’s lead product, XHANCE (fluticasone propionate) nasal spray, utilizes breath powered exhalation delivery system (EDS), to deliver a topically acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. XHANCE has a differentiated clinical profile with the potential to become part of the standard of care for this disease because it is able to deliver medication to the primary site of inflammation.

SPONSORED STORIES